Visiongain has launched a new pharma report ‘’Non-Invasive Prenatal Testing (NIPT) Market Report 2020-2030’’ by Product & Service {Consumables (Assay Kits & Reagents, Disposables), Instruments (Microarrays, Next-Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Next-Generation Sequencing Systems), Services}, Method (Biochemical Screening Tests, Cell-Free Dna in Maternal Plasma Tests, Ultrasound Detection), Application (Microdeletion Syndrome, Trisomy, Other Applications), Gestation Duration (0-12 Weeks, 13-24 Weeks, 25-36 Weeks), Pregnancy Risk (Low Risk Pregnancy Testing, High & Average Risk Pregnancy Testing), End Users (Diagnostic Laboratories, Hospitals), and Geography.

The global non-invasive prenatal testing (NIPT) market is anticipated to grow at a lucrative CAGR of 13.6% and anticipated to reach USD 14.86 Billion by 2030.

Due to the increasing prevalence of non-invasive procedures, the global non-invasive prenatal testing (NIPT) market is expected to see significant growth in the coming years. Improving reimbursement strategies and implementing new NIPT services are likely to support growth in the industry. Increasing awareness around the globe about these experiments will also generate lucrative opportunities in the future. Obstetricians are currently widely recommending these tests in the first trimester of pregnancy for early clinical testing.

Prenatal testing helps to assess fetal abnormality possibilities. The non-invasive design of these studies helps to avoid expensive and risky invasive procedures such as chorionic villus sampling (CVS) and amniocentesis. Payer increases in coverage related to average risk pregnancy tests are projected to accelerate the acceptance of amniocentesis testing and treatment of Down's syndrome. It is also expected to raise non-invasive prenatal support adoption rates.

Growing maternal age is projected to unfold far-reaching market growth opportunities. Advancing maternal age is responsible for several risks in health, such as high blood pressure, reduced fertility, miscarriage risk, and maternal death. It also increases the risk that babies will suffer chromosomal abnormalities. Potential baby defects may include weak muscle tone, breathing symptoms, problems related to the heart, and others. Increasing awareness of chromosomal anomalies detection and screening will fuel market growth in the years to come.

The existence of a strict regulatory framework for the approval of medical devices, however, may impede the market growth. Long authorization processes slow product growth and innovation. Also, it is anticipated that the lack of skilled practitioners would hinder the development of the demand for non-invasive prenatal testing.

NIPT screening methods include fetal cells in maternal blood tests, cell-free DNA in maternal plasma analysis, biochemical testing, and ultrasound detection. In the coming years, cell-free DNA throughout maternal plasma tests is expected to see a rise in their demand. This can be due to the increasing demand for NIPT research for cf-DNA-based techniques. Increasing government efforts to provide reproductive care are also likely to boost demand for these tests.

North America is recognized as one of the international arena's lucrative markets. High government spending on research and development (R&D) activities and the growth of whole-genome sequencing as a result of technologically advanced accessibility and the existence of well-established healthcare research infrastructure has given a boost to the regional market.

On the other hand, in the coming years, Asia Pacific is poised to display remarkable growth. Higher average maternal age, improved health care facilities, increased disposable income, and high prevalence of chromosomal abnormalities are some of the local market's key growth stimulants. Advancing maternal age and high-risk pregnancies in China are expected shortly to create lucrative opportunities for growth for the regional market.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global non-invasive prenatal testing market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the Non-Invasive Prenatal Testing (NIPT) market.

The comprehensive market report features companies such as Agilent Technologies, Inc., Beijing Genomics Institute, Berry Genomics, BGI, Bioarray S.L, F. Hoffmann-La Roche AG, GE Healthcare, Illumina Inc (Verinata Health Inc), Laboratory Corporation of America Holdings, Eurofins LifeCodexx GmbH, Natera Inc., Perkinelmer, Inc., Quest Diagnostics, Sequenom, Thermo Fisher Scientific, Inc., Yourgene Health among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.